Biologics
| R&D Pipeline | Indication | Project Progress | Objectives to be Achieved |
|---|---|---|---|
| F-627 | Chemotherapy-induced neutropenia | Approved in China and the United States,during marketing application review in the European Union | Global commercialization |
| F-652 | Alcoholic hepatitis | phase IIa clinical trials in China and the U.S. | Global commercialization |
| F-652 | Acute-on-chronic liver failure | phase II clinical trials in China and the U.S. | Global commercialization |
| F-652 | GVHD | phase IIa clinical trials in China and the U.S. | Global commercialization |
| F-652 | Necrotizing enterocolitis (often seen in newborns) | pre-clinical research | Global commercialization |
| F-899 | Growth hormone deficiency in children | phase I clinical trials in China | commercialization in China |
| GLP-1/GIP | Diabetes and obesity | pre-clinical research | Global commercialization |
| Multiple double-antibody projects | Tumor | pre-clinical research | Global commercialization |
| B-3E01 | diabetes | pre-clinical research | Global commercialization |
| B-3E02 | diabetes | pre-clinical research | Global commercialization |
| B-3E03 | diabetes | pre-clinical research | Global commercialization |
| B-3E07 | osteoporosis | pre-clinical research | Global commercialization |
Small Molecule
| Main Drug Projects | Indication | Project Progress | Objectives to be Achieved |
|---|---|---|---|
| YFH-6TM | Diuretics, for patients with congestive heart failure, ascites due to cirrhosis, and edema caused by kidney disease | process verification | Obtaining drug approval number |
| YFH-4YT | Allergic conjunctivitis | process verification | Obtaining drug approval number |
| YFH-3AL | Cough, sticky sputum, difficulty in sputum excretion and wheezing caused by acute and chronic respiratory diseases | process verification | Obtaining drug approval number |
| YFH-3YB | Hemorrhage caused by excessive heparin | process verification | Obtaining drug approval number |
| YFH-4AG | Leukemia, such as acute myeloid leukemia, acute lymphocytic leukemia, and acute transformation of chronic myelocytic leukemia | process verification | Obtaining drug approval number |
| YFH-3XM | Myasthenia gravis, postoperative functional dyspesia and urinary retention | process verification | Obtaining drug approval number |
| YFH-3FM | Upper gastrointestinal bleeding caused by peptic ulcer | upcoming application | Obtaining drug approval number |
| YFH-3MS | Acute skeletal muscle pain or discomfort | upcoming application | Obtaining drug approval number |
| YF-H-21YX | Cancer pain and postoperative pain | upcoming application | Obtaining drug approval number |
| YF-H-20NP | Ischemic nerve injury caused by cerebral vasospasm after aneurysmal subarachnoid hemorrhage | upcoming application | Obtaining drug approval number |
| YF-H-21YT | Allergic rhinitis and urticaria | BE/clinical trials | Obtaining drug approval number |
| Tirofiban Hydrochloride Injection | In combination with heparin, indicated for unstable angina pectoris and non-Q wave myocardial infarction (NQMI); cardiac ischemia complications related to sudden coronary occlusion | under review and approval | Obtaining drug approval number |
| Clofarabine Injection | Refractory or recurrent acute lymphocytic leukemia in children | under review and approval | Obtaining drug approval number |
| Proglycem Oral Suspension | Congenital hyperinsulinemic hypoglycemia (CHI) | under review and approval | Obtaining drug approval number |
| Dopamine Hydrochloride Injection | Shock syndrome | under review and approval | Obtaining drug approval number |
| Oxytocin Injection | Uterine bleeding; assessment of placental reserve (oxytocin challenge test) | under review and approval | Obtaining drug approval number |
| Main API Projects | Clinical Use | Project Progress |
|---|---|---|
| Stearic acid | Emulsifier, ointment base, lubricant, defoamer, etc. | Bundling review passed; on sale |
| Single and double stearic acid glycerin ester | Lubricant, emulsifier, antibacterial agent, ointment base, etc. | Bundling review passed; on sale |
| Cetostearyl alcohol | Lubricant, emulsifier, thickener, etc. | Bundling review passed; on sale |
| Octadecyl alcohol | Dispersant, emulsifier, defoamer, lubricant, etc. | Bundling review passed; on sale |
| Cetyl alcohol | Emulsifier, ointment base, defoamer, etc. | Bundling review passed; on sale |
| YFF-RC | Emulsifier, surfactant and thickener | Pharmaceutical research completed |
| YFF-RS | Defoamer and ointment based, widely used in oral and external pharmaceutical preparations | Pharmaceutical research completed |
| YFF-QZ/QB/QD/BZ | Bacteriostat | Pharmaceutical research completed |
| YFF-YS | A promoter for local penetration and transdermal absorption, rectal absorption, oral delivery and intestinal absorption, which can also be used to stabilize oil-in-water emulsion | Process verification |
| YFF-ZS | Lubricant and ointment base, widely used in oral and external pharmaceutical preparations | Process verification |
| YFF-WL | Coating agent, controlled-release carrier, etc. | Process verification |
| YFF-SL | Ointment base, coating material, etc. | Process verification |
| YF-H-20PG/PE | A pharmaceutical auxiliary material for oral use, which can improve absorption of water in intestinal tracts, thus improving constipation caused by lack of water in intestinal tracts of patients | Process validation |
| YFY-8YM | Multiple myeloma | Under pharmaceutical research |
| YFY-8TS | Regulating sleep | Under pharmaceutical research |
| YFY-8AZ | Anti-fungal infection | Under pharmaceutical research |
| YFY-8LE | Tachycardia arrhythmia during operation | Under pharmaceutical research |
| YFY-8KM | Multiple myeloma | Under pharmaceutical research |
| YFY-8QS | Used to increase systemic circulation pressure and alleviate symptoms in acute onset of tetralogy of Fallot | Under pharmaceutical research |
| YFY-8LA | Anti-epileptic | Under pharmaceutical research |
| YFY-8SS | Can relieve weak heartbeat, decreased blood pressure, dyspnea, etc. | Under pharmaceutical research |
| YF-H-20CJ | Used for treatment of acute leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, bronchogenic carcinoma, soft tissue sarcoma, neuroblastoma, etc. | Pharmaceutical research completed |
| YF-H-17AG-a | Leukemia, such as acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia (CML)-BC, etc. | Pharmaceutical research completed |
| YF-H-20AT | Induction of remission and maintenance therapy for acute myeloid leukemia and chronic myeloid leukemia (BC) | Process verification |
| YF-H-21YX | Cancer pain and postoperative pain | Process validation |
| Povidone iodine | A drug for surgical use and antiseptic | Approved |
| Phloroglucinol/Trimethyl phloroglucinol | Spasmolysis of smooth muscle | under review and approval |
| Oxytocin/Oxytocin solution | Uterine bleeding; testing placental reserve function (provocation test) | under review and approval |
| Clofarabine | Refractory or recurrent acute lymphocytic leukemia in children | under review and approval |
Synthetic Biology
| R&D Pipeline | Project Objectives | Project Progress | Objectives to be Achieved |
|---|---|---|---|
| YF-BUD | Further diversifying product lines | Completing the first milestone | Having comprehensive competitive advantages, and selling products on the global market |
| YF-PG | Further diversifying product lines | Completing the first milestone | Having comprehensive competitive advantages, and selling products on the global market |
| YF-GT | Further diversifying product lines | Completing the third milestone, and meeting the conditions for industrialization | Having comprehensive competitive advantages, and selling products on the global market |
| YF-RA | Further diversifying product lines | Completing the first milestone, and carrying out follow-up research | Having comprehensive competitive advantages, and selling products on the global market |
| YF-GB | Further diversifying product lines | Completing the first milestone | Having comprehensive competitive advantages, and selling products on the global market |
Traditional Chinese Medicine
| R&D Pipeline | Indication | Project Progress | Objectives to be Achieved |
|---|---|---|---|
| YFZ-1DJ | Intended for treatment and prevention of relapse of patients with opioid dependence | ongoing phase Ib clinical trials | Obtaining drug approval number |
| YFZ-1ZX | Exogenous wind-heat in children | completion of pre-clinical research | Obtaining drug approval number |
| YFZ-5YH | Cold and flu | ongoing phase II clinical trials | Obtaining drug approval number |
| YFZ-3YH | Invigorating qi and blood, nourishing blood and promoting blood circulation | completion of pharmaceutical research | Obtaining drug approval number |
| YFZ-3TH | Deficiency of blood and blood stasis syndrome | completion of pharmaceutical research | Obtaining drug approval number |
| YFZ-3BY | Gynecological yin deficiency with internal heat and blood disorder, etc. | completion of pharmaceutical research | Obtaining drug approval number |
| YFZ-3TJ | Irregular menstruation, gynecological inflammation and functional uterine bleeding | completion of pharmaceutical research | Obtaining drug approval number |